Boehringer Ingelheim taps Philogen DNA-encoded chemistry tech

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/Antiv3D)
(Image: iStock/Antiv3D)
Boehringer Ingelheim and Philogen have signed a multi-target research agreement to discover and optimize new small molecule therapeutics for unmet medical needs.

The collaboration leverages Philogen’s DNA-Encoded Chemistry technology and Encoded Self-Assembling Chemical (ESAC) platform.

According to the Swiss-Italian company, the complementary discovery technologies enable the screening of up to billions of small molecules. The technology also optimizes hit compounds in a “fully automatic, DNA-tagged, fragment-based drug discovery manner​.”

Philogen DNA-Encoded libraries are extremely pure and based on smart design in order to provide a rich diversity without the need to work with huge and poorly manageable libraries. Moreover, ESAC technology allows a very fast and efficient way to optimize initial hit compounds and perform lead expansion,​” a Philogen representative told Outsourcing-Pharma.com.

Philogen is delighted to have expanded its ongoing collaborations with Boehringer Ingelheim beyond the area of biologics​,” they added.

The companies have previously worked together as part of a collaboration to explore investigate treatment approaches for Acute Myeloid Leukemia (AML).

Financial details of the agreement were not released.

Related news

Related products

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers